Connect with us

Life Sciences

Body Vision Medical Announces Market Entry and First Customer in India

Body Vision signs exclusive distribution agreement with SCHILLER Healthcare India and plans for first LungVisionSystem installation at Yashoda Hospitals…

Published

on

This article was originally published by AITHORITY
Body Vision Medical Announces Market Entry and First Customer in India

Body Vision signs exclusive distribution agreement with SCHILLER Healthcare India and plans for first LungVisionSystem installation at Yashoda Hospitals in Hyderabad

Body Vision Medical, a leader in AI-driven, intraoperative imaging, announced  they have signed an exclusive distribution agreement with SCHILLER Healthcare India Pvt. Ltd., and that Yashoda Hospitals in Hyderabad plans to acquire a LungVision System, which, upon installation, will be the first in India.

Body Vision Medical’s LungVision System uses artificial intelligence (AI) to transform X-ray images from any C-arm into real-time, intraoperative CT scans. This empowers bronchoscopists to biopsy from smaller, more difficult-to-access lung lesions at an earlier stage, thus maximizing the likelihood of an early diagnosis for lung cancer patients and improving odds for survival.

“Being at the forefront of the fight against cancer, Yashoda Hospitals strive to offer the latest in cancer diagnostics,” said Dr. Hari Kishan Gonuguntla, Lead, Interventional Pulmonology Division at Yashoda Hospitals. “The adoption of cutting-edge intraoperative imaging technologies like the Body Vision LungVision System, combined with our clinical expertise, has the potential to improve the quality of life of lung cancer patients through earlier diagnosis and shortening the diagnosis to therapy time.”

Data to Power BI : 3 Ways to Export ServiceNow Data to Power BI

This entry into India supports Body Vision Medical’s aggressive growth strategy aimed at making the benefits of LungVision accessible to pulmonologists and lung patients in 60 markets over the next three years.

“This is the first step in democratizing LungVision imaging technology to India’s nearly 1.4 billion residents and empowering pulmonologists to diagnose their lung patients more accurately at an earlier stage,” said David Webster, CEO of Body Vision Medical. “Limited lung cancer screening in India today means that the projected 100,000¹ new cases annually is likely underestimated and patients diagnosed with lung cancer only have a 10% 5-year survival rate², one of the lowest in the world due to being diagnosed at a late stage where treatment options are limited and survival rates poor.”

Body Vision Medical’s strategic partnership with SCHILLER Healthcare India will accelerate Body Vision’s penetration of the Indian market.

Browse The Complete News About Blockchain : Blockchain Partnership: PraSaga and Metahug Gamify Web3 Education Via Roblox

“We are pleased to collaborate with Body Vision Medical to distribute and support their products in India,” said Vikram Sanghvi, CEO and MD of SCHILLER Healthcare India Pvt. Ltd. “Their cutting-edge AI Intraoperative 3D imaging system meets the strictest requirements for quality and we are confident they will live up to the expectations of our clients and partners across India.”

Next-gen AI-On-Demand Platform :  European Commission Pumps in $9.15 Million to Develop Next-gen AI-On-Demand Platform

[To share your insights with us, please write to sghosh@martechseries.com] 

The post Body Vision Medical Announces Market Entry and First Customer in India appeared first on AiThority.

diagnostics


artificial intelligence


Life Sciences

Wittiest stocks:: Avalo Therapeutics Inc (NASDAQ:AVTX 0.00%), Nokia Corp ADR (NYSE:NOK 0.90%)

There are two main reasons why moving averages are useful in forex trading: moving averages help traders define trend recognize changes in trend. Now well…

Continue Reading
Life Sciences

Spellbinding stocks: LumiraDx Limited (NASDAQ:LMDX 4.62%), Transocean Ltd (NYSE:RIG -2.67%)

There are two main reasons why moving averages are useful in forex trading: moving averages help traders define trend recognize changes in trend. Now well…

Continue Reading
Life Sciences

Asian Fund for Cancer Research announces Degron Therapeutics as the 2023 BRACE Award Venture Competition Winner

The Asian Fund for Cancer Research (AFCR) is pleased to announce that Degron Therapeutics was selected as the winner of the 2023 BRACE Award Venture Competition….

Continue Reading

Trending